Shanghai Fosun Pharmaceutical Deal History & Licensing Activity
Shanghai Fosun Pharmaceutical is a large biotech headquartered in China. Over the past three years, Shanghai Fosun Pharmaceutical has been involved in 2 licensing and acquisition transactions, with a primary focus on Other (4 deals). The company currently has 13 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
2
Active Trials
13
Top Modality
Other
Focus Area
Solid Tumors
Shanghai Fosun Pharmaceutical Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Shanghai Fosun Pharmaceutical in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Organon | Sun Pharma | Other | Unknown | acquisition | Jun 15, 2026 |
| Alzheimer's disease asset | Fosun | Other | Unknown | option | May 15, 2026 |
Shanghai Fosun Pharmaceutical Pipeline Focus
Therapeutic areas and modalities where Shanghai Fosun Pharmaceutical is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Shanghai Fosun Pharmaceutical Strategic Signals
Key indicators of Shanghai Fosun Pharmaceutical's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Shanghai Fosun Pharmaceutical Clinical Pipeline
Shanghai Fosun Pharmaceutical has 13 active clinical trials across 3 development phases.
4
Phase 1
6
Phase 2
3
Phase 3
See How Your Asset Matches Shanghai Fosun Pharmaceutical's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Shanghai Fosun Pharmaceutical Licensing & Deal Activity
Shanghai Fosun Pharmaceutical is a large biotech company based in China that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Shanghai Fosun Pharmaceutical ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Shanghai Fosun Pharmaceutical include Solid Tumors (3 deals and trials), Mega Deals (2 deals and trials), Neurology (2 deals and trials), and Autoimmune (1 deal and trial). In terms of modality, Shanghai Fosun Pharmaceutical has shown particular interest in other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Shanghai Fosun Pharmaceutical and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Shanghai Fosun Pharmaceutical's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.